ChemoCentryx (CCXI) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
ChemoCentryx Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 6, 2015 4:05 PM EDT- Completed enrollment in the European Vasculitis Phase II CLEAR trial of C5aR inhibitor CCX168; top line data expected by year-end 2015 -
- North American Vasculitis Phase II CLASSIC trial of CCX168 reaches halfway mark in target patient enrollment -
- Initiated Phase II proof-of-concept trial in atypical hemolytic uremic syndrome with CCX168 -
- Pancreatic cancer proof-of-concept trial with CCX872 progressing -
- Conference Call Today at 5:00 p.m. Eastern... More
